Here are the S-1 registration statements from Kardigan, Inc. (KARD) in our archive over the last 12 months, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
An S-1 covers the registration statement a company files to sell shares publicly, so if you follow KARD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full KARD filings page.
Kardigan, Inc. plans an initial public offering of 23,333,334 shares of common stock, with an estimated price range of $14.00 to $16.00 per share. The company has applied to list on the Nasdaq Global Market under the symbol “KARD.”
Kardigan is a clinical-stage precision cardiovascular therapeutics company with three late-stage product candidates and a proprietary real‑world data and analytics platform called Prolaio. Prolaio includes FDA‑regulated devices and 510(k)-cleared algorithms that collect high‑frequency physiologic data from wearables to support clinical trials and digital endpoints.
The company reported a net loss of $191.9 million for 2025 and $56.1 million for the three months ended March 31, 2026, with an accumulated deficit of $337.2 million. As of March 31, 2026, cash, cash equivalents and short‑term investments totaled $287.1 million, but management and auditors concluded there is substantial doubt about its ability to continue as a going concern even after the offering. Kardigan qualifies as an emerging growth company and smaller reporting company, allowing reduced disclosure and extended transition for new accounting standards.